demephan® p.sv.inj.f 50mg/vial
demo abee 21 ΧΛΜ. ΕΘΝ.ΟΔΟΥ ΑΘΗΝΩΝ-ΛΑΜΙΑΣ, 145 68 145 68, ΚΡΥΟΝΕΡΙ 8161802 - melphalan hydrochloride - p.sv.inj.f (ΚΟΝΙΣ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΕΝΕΣΙΜΟΥ ΔΙΑΛΥΜΑΤΟΣ ΚΑΙ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 50mg/vial - melphalan hydrochloride 55,97mg - melphalan
pepaxti pd.c.so.in 20 mg/vial
melphalan flufenamide hydrochloride - pd.c.so.in (ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 20 mg/vial - melphalan flufenamide hydrochloride 20mg - melphalan flufenamide
alkeran/glaxo wellcome 2mg/tab δισκιο
ΙΦΕΤ ΑΕ (0000004652) 18ο χλμ. Λεωφ. Μαραθώνος,, 153 51, Παλλήνη Αττικής, 153 51 - melphalan - ΔΙΣΚΙΟ - 2mg/tab - 0000148823 melphalan 0.000000 - melphalan
melfalan/glaxo smith kline tab 2mg/tab
ΙΦΕΤ ΑΕ 18ο χλμ. Λεωφ. Μαραθώνος,, 153 51 153 51, Παλλήνη Αττικής 210.6603400-6603522 - melphalan - tab (ΔΙΣΚΙΟ) - 2mg/tab - melphalan
alkeran/glaxo wellcome tab 5mg/tab
ΙΦΕΤ ΑΕ 18ο χλμ. Λεωφ. Μαραθώνος,, 153 51 153 51, Παλλήνη Αττικής 210.6603400-6603522 - melphalan - tab (ΔΙΣΚΙΟ) - 5mg/tab - melphalan
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - Αντινεοπλασματικοί παράγοντες - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
alkeran 2mg/tab c.tab
glaxo wellcome a.e.b.e. - melphalan - ΕΠΙΚΑΛΥΜΜΕΝΟ ΔΙΣΚΙΟ - 2mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
alkeran 5mg/tab c.tab
glaxo wellcome a.e.b.e. - melphalan - ΕΠΙΚΑΛΥΜΜΕΝΟ ΔΙΣΚΙΟ - 5mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
alkeran 50mg/vial ly.pd.inj
glaxo wellcome a.e.b.e. - melphalan - ΕΝΕΣΙΜΟ ΛΥΟΦΙΛΟ - 50mg/vial - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ